NeuroBo Pharmaceuticals (NRBO)
(Delayed Data from NSDQ)
$3.23 USD
+0.09 (2.87%)
Updated Apr 29, 2024 03:59 PM ET
After-Market: $3.23 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for NeuroBo Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 16 | 20 | 15 | 30 | 20 |
Income After Depreciation & Amortization | -16 | -20 | -15 | -30 | -20 |
Non-Operating Income | 3 | 6 | 0 | 0 | -1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -12 | -14 | -15 | -30 | -21 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -12 | -14 | -15 | -30 | -21 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -12 | -14 | -15 | -30 | -21 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -16 | -20 | -15 | -30 | -20 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -16 | -20 | -15 | -30 | -20 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 5.07 | 0.32 | 0.10 | 0.07 | 0.02 |
Diluted EPS Before Non-Recurring Items | -2.46 | -43.44 | -158.56 | -182.58 | -980.18 |
Diluted Net EPS (GAAP) | -2.46 | -43.44 | -158.56 | -439.64 | -980.18 |
Fiscal Year end for NeuroBo Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 5.67 | 3.89 | 3.80 | 2.52 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -5.67 | -3.89 | -3.80 | -2.52 |
Non-Operating Income | NA | 0.05 | -0.09 | 3.07 | -0.08 |
Interest Expense | NA | -0.30 | -0.16 | 0.00 | 0.00 |
Pretax Income | NA | -5.31 | -3.82 | -0.73 | -2.60 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -5.31 | -3.82 | -0.73 | -2.60 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -5.31 | -3.82 | -0.73 | -2.60 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 5.08 | 5.06 | 5.06 |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.72 | -0.16 | -0.48 |
Diluted Net EPS (GAAP) | NA | -1.10 | -0.72 | -0.16 | -0.48 |